Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Total Voting Rights

30 Apr 2019 07:00

RNS Number : 4628X
Polarean Imaging PLC
30 April 2019
 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Total Voting Rights

 

Polarean Imaging plc (AIM: POLX), the medicalimaging technology company, with a proprietary drugdevice combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 101,435,933 ordinary shares of £0.00037 each.

 

The total issued share capital of the Company consists of 101,435,933 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

Enquiries:

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman

 

 

 

 

 

 

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

 

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVREAKLNAFLNEFF
Date   Source Headline
15th Feb 20237:00 amRNSInvestor presentation
13th Feb 20232:05 pmRNSSecond Price Monitoring Extn
13th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 202311:05 amRNSSecond Price Monitoring Extn
13th Feb 202311:00 amRNSPrice Monitoring Extension
13th Feb 20239:05 amRNSSecond Price Monitoring Extn
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Feb 20237:00 amRNSCompany Update
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20234:25 pmRNSFDA grants New Chemical Entity designation
27th Jan 20237:00 amRNSBlock listing six monthly return
28th Dec 20229:05 amRNSSecond Price Monitoring Extn
28th Dec 20229:00 amRNSPrice Monitoring Extension
28th Dec 20227:00 amRNSFDA Approves XENOVIEW™ (Xe 129 hyperpolarized)
3rd Oct 202211:05 amRNSSecond Price Monitoring Extn
3rd Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSUpdate on New Drug Application
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 202211:06 amRNSSecond Price Monitoring Extn
22nd Sep 202211:00 amRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:04 amRNSUpdate on New Drug Application
31st Aug 20227:00 amRNSHalf-year Report
26th Aug 20227:00 amRNSDirectorate appointment
4th Aug 20224:40 pmRNSSecond Price Monitoring Extn
4th Aug 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSTotal voting rights and block listing return
8th Jul 20227:00 amRNSSystem delivery
29th Jun 20224:35 pmRNSResult of AGM
18th May 20227:00 amRNSFinal Results
11th May 20227:00 amRNSNotice of Results
11th May 20227:00 amRNSOxford research collaboration in long COVID
5th May 20227:00 amRNSDirectorate Change
29th Apr 20227:00 amRNSTotal Voting Rights
25th Apr 20227:00 amRNSNew system order
20th Apr 20227:00 amRNSNew Drug Application Resubmission update
14th Apr 20227:00 amRNSAppointment of Non-Executive Director
8th Apr 20227:00 amRNSExercise of Options and Total Voting Rights
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 202211:06 amRNSSecond Price Monitoring Extn
31st Mar 202211:00 amRNSPrice Monitoring Extension
31st Mar 20229:00 amRNSPrice Monitoring Extension
31st Mar 20227:00 amRNSNew Drug Application Resubmission
25th Feb 20227:00 amRNSTotal Voting Rights
14th Feb 20227:00 amRNSNew system order
28th Jan 20227:01 amRNSBlock Listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.